AMINO has a new partner for the distribution of its high quality amino acids and related substances in the CIS region. Therefore, AMINO entered a cooperation with the Czech company IMCoPharma that represents the basis for the distribution of AMINO´s products within the CIS territory by IMCoPharma.
In the last weeks AMINO has demolished its former administration building in order to create additional space for the expansion of its production capacity. It is intended to increase the production output of the plant immediately adjacent to the plot and specifically to supplement our technologies and processes.
Amino GmbH today launched L-methionine amino acid as a safe and effective active pharmaceutical ingredient and nutritional substance. Amino produces pharmaceutical-grade L-methionine in its state-of-the-art facility in Frellstedt, Germany, deriving the crude material from modern biotechnological methods, not through chemical synthesis. The entire L-methionine manufacturing process is free of animal-derived material, and does not use solvents at any point.
Amino GmbH has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for the amino acid L-alanine as part of its strategic intent to supplement and complete the line of pharmaceutical-grade amino acid products.
Amino has in the context of its sustainability program and specifically its energy policy committed to closely monitoring its electricity, gas and water – with a focus on cooling water – consumption and subsequently its reduction. An energy management system based on DIN ISO 50001:2011 was introduced and successfully certified.
“The fermentation of amino acids at Danisco’s Grindsted location presents a major strategic move towards a backward integration of our supply chain”, states Dr. Lutz Thomas, managing director of Amino GmbH.
Since its restructuring AMINO GmbH has grown its business substantially. In order to sustain its market international presence and to accelerate the development of the site in Frellstedt a step towards further expanding the skill base has been taken.
The expansion of Frellstedt plant’s production capacity for pharma-grade amino acids forms the backbone for the further enhancement for AMINO’s product offer. By adding L-proline, DL-/L-aspartic acid and L-serine in pharma-oral and pyrogen-free quality AMINO broadens its range of products.
The AMINO GmbH is expanding its production capacity at its site in Frellstedt. The reinforcement of its production technology and the specifically the duplication of the annual output capacity primarily targeted at amino acids from fermentation are the focus of the plant expansion.
AMINO GmbH has been granted Certificates of Suitability (CEPs) by the European Directorate for the Quality of Medicines (EDQM) for the production of isoleucine and threonine via the company’s state-of-the-art fermentation process.
Following a comprehensive audit and inpection, AMINO GmbH has been granted a production permit according to §13 paragraph 1 of the German Drug Act by the regulatory authorities of Brunswick and Oldenburg.
A new AMINO has emerged with the completion of a leveraged management buyout of the amino acids business of AMINO GmbH. And now the company’s vision of becoming a leading supplier of specialty amino acids to the global marketplace is powered by the determination of its new management team.